Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)

Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)

Cushing’s disease is associated with increased morbidity and mortality. Osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid, sustained mean urinary free cortisol (mUFC) normalization in Cushing’s disease patients in two Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734)....

Full description

Saved in:
Bibliographic Details
Main Authors: Akira Shimatsu, Beverly MK Biller, Maria Fleseriu, Rosario Pivonello, Eun Jig Lee, Rattana Leelawattana, Jung Hee Kim, Rama Walia, Yerong Yu, Zhihong Liao, Andrea Piacentini, Alberto M Pedroncelli, Peter J Snyder
Format: Article
Language:English
Published: The Japan Endocrine Society 2024-12-01
Series:Endocrine Journal
Subjects:
cushing’s syndrome
clinical trial
efficacy
safety
race
Online Access:https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0153/_html/-char/en
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0153/_html/-char/en

Similar Items